Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase NA 1Phase 4 1

Status

Completed 3

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Prostatic Neoplasms 3

Interventions

Cyclophosphamide 517Bevacizumab 488Carboplatin 424pembrolizumab 388Paclitaxel 385Gemcitabine 372Cisplatin 366Docetaxel 323Rituximab 316Radiotherapy 296Nivolumab 247Doxorubicin 243Dexamethasone 240Fluorouracil 225Capecitabine 214Oxaliplatin 211Erlotinib Hydrochloride 206fludarabine phosphate 201Etoposide 188Cetuximab 186Lenalidomide 177Pemetrexed 176Bortezomib 174Trastuzumab 173Filgrastim 171fludarabine 166Prednisone 166Leucovorin 166Cytarabine 166Irinotecan 161

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Has results × Finasteride × Clear all
NCT02213107 2024-11-13

Enzalutamide & Dutasteride/Finasteride as 1st Line Treatment for Patients =/> 65 Years Old With Prostate Cancer.

University of Rochester

Phase 2 Completed
43 enrolled 10 charts
Genitourinary

Prostatic Neoplasms

NCT00736645 2023-10-02

Selenomethionine and Finasteride Before Surgery or Radiation Therapy in Treating Patients With Stage I or Stage II Prostate Cancer

Roswell Park Cancer Institute

Phase 2 Completed
55 enrolled 11 charts
Genitourinary

Prostatic Neoplasms

NCT00438464 2016-03-09

Finasteride in Treating Patients With Stage II Prostate Cancer Who Are Undergoing Surgery

National Cancer Institute (NCI)

Phase 2 Completed
204 enrolled 28 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡